Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mark S. Boguski is active.

Publication


Featured researches published by Mark S. Boguski.


Nature Genetics | 1994

Issues in searching molecular sequence databases

Stephen F. Altschul; Mark S. Boguski; Warren Gish; John C. Wootton

Sequence similarity search programs are versatile tools for the molecular biologist, frequently able to identify possible DNA coding regions and to provide clues to gene and protein structure and function. While much attention had been paid to the precise algorithms these programs employ and to their relative speeds, there is a constellation of associated issues that are equally important to realize the full potential of these methods. Here, we consider a number of these issues, including the choice of scoring systems, the statistical significance of alignments, the masking of uninformative or potentially confounding sequence regions, the nature and extent of sequence redundancy in the databases and network access to similarity search services.


Cell | 1990

The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins

R. Ballester; Douglas A. Marchuk; Mark S. Boguski; Ann M. Saulino; Roxanne Letcher; Michael Wigler; Francis S. Collins

The von Recklinghausen neurofibromatosis locus, NF1, encodes a protein with homology restricted to the catalytic region of the RAS GTPase-activating protein, GAP, and with extensive homology to the IRA1 and IRA2 gene products of the yeast S. cerevisiae. A segment of the NF1 cDNA gene, expressed in yeast, can complement loss of IRA function and can inhibit both wild-type and mutant activated human H-ras genes that are coexpressed in yeast. Yeast expressing the NF1 segment have increased H-ras GTPase-stimulating activity. These studies indicate that the NF1 gene product can interact with RAS proteins and demonstrate structural and functional similarities and differences among the GAP, IRA1, IRA2, and NF1 proteins.


Cell | 1990

A repeating amino acid motif in CDC23 defines a family of proteins and a new relationship among genes required for mitosis and RNA synthesis

Robert S. Sikorski; Mark S. Boguski; Mark Goebl; Philip Hieter

We have identified and characterized a novel, repeating 34 amino acid motif (the TPR motif) that is reiterated several times within the CDC23 gene product of S. cerevisiae. Multiple copies of this motif were discovered in five other proteins, three encoded by cell division cycle genes required to complete mitosis and two involved in RNA synthesis. Quantitative sequence analyses suggest the existence of a common underlying structure in each TPR unit that consists of amphipathic alpha-helical regions punctuated by proline-induced turns. The TPR motif defines a new family of genes and an important structural unit common to several proteins whose functions are required for mitosis and RNA synthesis.


Genomics | 1991

cDNA cloning of the type 1 neurofibromatosis gene : Complete sequence of the NF1 gene product

Douglas A. Marchuk; Ann M. Saulino; Roxanne Tavakkol; Manju Swaroop; Margaret R. Wallace; Lone B. Andersen; Anna L. Mitchell; David H. Gutmann; Mark S. Boguski; Francis S. Collins

Von Recklinghausen neurofibromatosis, or type 1 neurofibromatosis (NF1), is a common autosomal dominant disorder characterized by abnormalities in multiple tissues derived from the embryonic neural crest. Portions of the gene have been recently identified by positional cloning, and sequence analysis has shown homology to the GTPase activating protein (GAP) family. In this report we present the results of an extensive cDNA walk resulting in the cloning of the complete coding region of the NF1 transcript. Analysis of the sequences reveals an open reading frame of 2818 amino acids, although alternatively spliced products may code for different protein isoforms. The gene extends for approximately 300 kb on chromosome 17, with its promoter in a CpG-rich island.


Nature Genetics | 1998

Data management and analysis for gene expression arrays

Olga Ermolaeva; Mohit Rastogi; Kim D. Pruitt; Gregory D. Schuler; Michael L. Bittner; Yidong Chen; Richard Simon; Paul S. Meltzer; Jeffrey M. Trent; Mark S. Boguski

Microarray technology makes it possible to simultaneously study the expression of thousands of genes during a single experiment. We have developed an information system, ArrayDB, to manage and analyse large-scale expression data. The underlying relational database was designed to allow flexibility in the nature and structure of data input and also in the generation of standard or customized reports through a web-browser interface. ArrayDB provides varied options for data retrieval and analysis tools that should facilitate the interpretation of complex hybridization results. A sampling of ArrayDB storage, retrieval and analysis capabilities is available (http://www.nhgri.nih.gov/DIR/LCG/15K/HTML/), along with information on a set of approximately 15,000 genes used to fabricate several widely used microarrays. Information stored in ArrayDB is used to provide integrated gene expression reports by linking array target sequences with NCBIs Entrez retrieval system, UniGene and KEGG pathway views. The integration of external information resources is essential in interpreting intrinsic patterns and relationships in large-scale gene expression data.


Pharmacogenetics | 2001

The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants

Jiong Zhang; Peter M. Kuehl; Eric D. Green; Jeffery W. Touchman; Paul B. Watkins; Ann K. Daly; Stephen D. Hall; Patrick Maurel; Mary V. Relling; Cynthia Brimer; Kazuto Yasuda; Steven A. Wrighton; Michael L. Hancock; Richard B. Kim; Stephen C. Strom; Kenneth Thummel; Christopher G. Russell; James R. Hudson; Erin G. Schuetz; Mark S. Boguski

The pregnane X receptor (PXR)/steroid and xenobiotic receptor (SXR) transcriptionally activates cytochrome P4503A4 (CYP3A4) when ligand activated by endobiotics and xenobiotics. We cloned the human PXR gene and analysed the sequence in DNAs of individuals whose CYP3A phenotype was known. The PXR gene spans 35 kb, contains nine exons, and mapped to chromosome 13q11-13. Thirty-eight single nucleotide polymorphisms (SNPs) were identified including six SNPs in the coding region. Three of the coding SNPs are non-synonymous creating new PXR alleles [PXR*2, P27S (79C to T); PXR*3, G36R (106G to A); and PXR*4, R122Q (4321G to A)]. The frequency of PXR*2 was 0.20 in African Americans and was never found in Caucasians. Hepatic expression of CYP3A4 protein was not significantly different between African Americans homozygous for PXR*1 compared to those with one PXR*2 allele. PXR*4 was a rare variant found in only one Caucasian person. Homology modelling suggested that R122Q, (PXR*4) is a direct DNA contact site variation in the third alpha-helix in the DNA binding domain. Compared with PXR*1, and variants PXR*2 and PXR*3, only the variant PXR*4 protein had significantly decreased affinity for the PXR binding sequence in electromobility shift assays and attenuated ligand activation of the CYP3A4 reporter plasmids in transient transfection assays. However, the person heterozygous for PXR*4 is normal for CYP3A4 metabolism phenotype. The relevance of each of the 38 PXR SNPs identified in DNA of individuals whose CYP3A basal and rifampin-inducible CYP3A4 expression was determined in vivo and/or in vitro was demonstrated by univariate statistical analysis. Because ligand activation of PXR and upregulation of a system of drug detoxification genes are major determinants of drug interactions, it will now be useful to extend this work to determine the association of these common PXR SNPs to human variation in induction of other drug detoxification gene targets.


FEBS Letters | 1995

Threading analysis suggests that the obese gene product may be a helical cytokine

Thomas Madej; Mark S. Boguski; Stephen H. Bryant

The ob gene encodes a protein that, in mutant form, is associated with obesity and type II diabetes in mice. Sequence analysis has revealed no similarities to other proteins, however, and no clues as to possible functions. The possibility nonetheless remains that ob is functionally or ancestrally related to other proteins, whose sequences are divergent to the point that only a comparison of three‐dimensional structures might detect relationship. To explore this possibility, we conduct a ‘threading’ search of a 3‐dimensional structure database, to determine whether the ob protein might adopt a fold similar to any known structure. This search reveals that the ob sequence is compatible, at a significance level of P < 0.05, with structures from the family of helical cytokines that includes interleukin‐2 and growth hormone. A structural model of ob based upon these results is physically and biologically plausible and leads to testable predictions, including the prediction that ob may activate the JAK‐STAT pathway, via binding to a receptor resembling those of the cytokine family.


Genomics | 1990

The National Center for Biotechnology Information

Dennis Benson; Mark S. Boguski; David J. Lipman; James Ostell

You may not have heard of the National Center for Biotechnology Information (NCBI), but chances are good that you’ve used one of our resources, such as the PubMed database of biomedical literature or the BLAST DNA and protein sequence similarity search tool. And you’re not alone: Each day, over 2 million people access NCBI databases and download a total of more than 3 terabytes (trillion bytes) of data.


Science | 2009

Repurposing with a Difference

Mark S. Boguski; Kenneth D. Mandl; Vikas P. Sukhatme

Consumer activism, genetic information, and social networking technologies are creating many opportunities for drug repurposing. There is widespread belief that current models of drug discovery and development need revamping and reinvention in order to make pharmaceutical research and development (R&D) more predictable, reliable, and less costly. We suggest a novel approach to this challenge that involves profound changes in the way postmarketing surveillance data are gathered and used. This approach capitalizes on recent advances in molecular medicine, human genomics, and information technology, as well as an increasingly sophisticated public eager for solutions to their unmet medical needs. Novel business models and imaginative legal and regulatory reforms will be critical to fulfill this promise and to maximize its impact.


Somatic Cell and Molecular Genetics | 1993

Neurofibromatosis type 1 gene product (neurofibromin) associates with microtubules

Paula E. Gregory; David H. Gutmann; Anna L. Mitchell; Soochul Park; Mark S. Boguski; Tyler Jacks; Deborah L. Wood; Richard Jove; Francis S. Collins

The neurofibromatosis type 1 (NF1) gene was recently identified by positional cloning and found to encode a protein with structural and functional homology to mammalian and yeast GTPase-activating proteins (GAPs). Using antibodies directed against the NF1 gene product, a protein of ∼250kDa was identified and termed neurofibromin. Double-indirect immunofluorescent labeling with anti-neurofibromin and anti-tubulin antibodies demonstrates that neurofibromin associates with cytoplasmic microtubules. Immunoblotting of microtubule-enriched cytoplasmic fractions, using antibodies generated against neurofibromin, shows that neurofibromin copurifies with microtubules. When portions of neurofibromin are expressed in Sf9 insect cells they associate with polymerized microtubules; furthermore, the critical residues for this interaction reside within the GAP-related domain of neurofibromin. The unexpected association of neurofibromin with microtubules suggests that neurofibromin is involved in microtubule-mediated intracellullar signal transduction pathways.

Collaboration


Dive into the Mark S. Boguski's collaboration.

Top Co-Authors

Avatar

Jeffrey I. Gordon

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Francis S. Collins

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

John M. Taylor

University of California

View shared research outputs
Top Co-Authors

Avatar

Jane M. Weisemann

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Philip Hieter

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

Peter M. Kuehl

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Allen M. Spiegel

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge